Affiliation:
1. Assistant Professor, Department of Pathology, Mahadevappa Rampure Medical College. Kalaburagi. Karnataka state.
2. Post graduate trainee, Department of Pathology. Mahadevappa Rampure Medical College. Kalaburagi. Karnataka State.
3. Post graduate trainee. Department of Pathology. Mahadevappa Rampure Medical college. Kalaburagi. Karnataka state.
Abstract
Introduction Glioblastoma is the most aggressive and deadly of all brain tumors. It accounts for 12-15% of all intracranial neoplasm and 50-60%
(1) of all astrocytic tumours Even though Glioblastoma is a quite rare tumor with a global incidence rate of less than 10 per 100,000 it signicantly
(2) impacts the life of the affected patients due to its poor prognosis with a median survival time of only 14-15 months from the time of diagnosis .
Materials And MethodsA total of 21 cases of Glioblastomas were studied over a period of 5yrs from 2017 to 2022. Intraoperative squash smears
were prepared, stained with toluidine blue, “Hematoxylin and Eosin” and examined. The residual tissue samples were processed for parafn
section and stained by Hematoxylin and Eosin and IHC was done wherever necessary. Histopathological examination was carried out for
conrmative diagnosis and squash smear cytology diagnoses were correlated with nal histopathological ndings. Out of 21 cases, 12 Results
were Glioblastoma, 7 were Gliosarcoma, one each of Epithelioid Glioblastoma and Gemistocytic Glioblastoma. Male to Female Ratio is 2.5:1.
Most common clinical presentations were Headache, giddiness, vomiting and weakness/paresis in lower limbs. Intraoperative Squash smear
cytology could diagnose high grade gliomas with 100 % accuracy which was concordant with histopathological diagnosis. Squash Conclusion
smear cytology ndings, if interpreted with clinical picture and radio-imaging ndings, will help to reach an accurate and rapid diagnosis of
intracranial tumor, but histopathology remains gold standard for conrmation of diagnosis and differentiating the variants.
Subject
Mechanical Engineering,Mechanics of Materials,Biomedical Engineering,Medicine (miscellaneous),Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,General Medicine,General Immunology and Microbiology,Endocrine and Autonomic Systems,Endocrinology, Diabetes and Metabolism,Pharmacology (medical),Psychiatry and Mental health,Pharmacology,General Nursing,Food Science,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference17 articles.
1. Khanna M, Mandritta P and Roy S: Clinicopathological study of 115 cases of Glioblastoma multiforme with special reference to Gliosarcoma – An original research article. Int J Pharm Sci Res 2013; 4(6); 2384-2392.
2. Farina Hanif, Kanza Muzaffar, Kashkashian Parveen, Saima M Malhi and Shabana U Simjee. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through clinical presentation and Treatment: Asian Pac J Cancer Prev. 2017;18(1):3-9.
3. David N. Louis, Arie Perry, Pieter Wesseling, Daniel J. Brat, Ian A. Cree, Dominique Figarella-Branger, Cynthia Hawkins, H. K. Ng, Stefan M. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary: Neuro-Oncology 23(8), 1231–1251, 2021.
4. Greenfield’s Neuropathology 9th Edition: vol-I:1650-1659.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. NEngl J Med. 2005 Mar 10;352(10):987-96.